Compare HKD & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HKD | CTKB |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.3M | 541.1M |
| IPO Year | 2021 | 2021 |
| Metric | HKD | CTKB |
|---|---|---|
| Price | $1.71 | $5.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.56 |
| AVG Volume (30 Days) | 147.2K | ★ 1.3M |
| Earning Date | 02-26-2027 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $193,015,000.00 |
| Revenue This Year | N/A | $3.94 |
| Revenue Next Year | N/A | $6.59 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 17.67 |
| 52 Week Low | $1.26 | $3.31 |
| 52 Week High | $5.47 | $6.21 |
| Indicator | HKD | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 56.58 |
| Support Level | $1.63 | $4.17 |
| Resistance Level | $1.73 | $6.21 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 42.86 | 43.78 |
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.